Global Tenosynovitis Drugs Market
Global Tenosynovitis Drugs Market

Tenosynovitis Drugs Comprehensive Study by Product type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Antibiotics, Corticosteroids), End user (Hospitals, Drugstores, Others) Players and Region - Global Market Outlook to 2027

Tenosynovitis Drugs Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Jan 2022 Edition 236 Pages 85 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Tenosynovitis drugs are the drugs that are used to treat conditions like inflammation of a tendon and its respective synovial sheath. This inflammation can causes from a great number of distinct processes, including idiopathic, infectious, and inflammatory causes. Usually hands, wrists and feet are often affected in these type of inflammation. Common causes are injury, repetitive use and infection. Some of the symptoms of tenosynovitis include pain, swelling and difficulty moving the affected joint.

Market Drivers
  • Rising Prevalence of Inflammatory Diseases

Market Trend
  • Growing Use of Tenosynovitis Drugs for Arthritis Treatment

Restraints
  • The Side Effect of the Tenosynovitis drugs

Opportunities
Increasing Influence of Generic Drugs

Players Covered in the Study are:
GSK (United Kingdom), Pfizer (United States), Grunenthal (Germany), Sanofi (France), Bayer (Germany), AstraZeneca (United Kingdom), Lilly (United States), Endo International (Ireland), Merck (United States) and Yunnan Baiyao (China)

The Global Tenosynovitis Drugs market is gaining huge competition due to involvement of United Kingdom companies that constantly invest in research & development to meet market expectation with new innovation.

What can be explored with Tenosynovitis Drugs study:
• Where Tenosynovitis Drugs industry stands in scaling its end use implementations
• What concrete benefits would result from scaled initiatives by Players
• Where Players should focus their investments cycle
• Key success factors and recommendations for upscaling future growth.
• Target Market / Country and Key Business Segments

Available Customization:
List of players that can be included in the study on immediate basis are Teikoku Seiyaku (Japan), Teva (Israel) and Mikasa Seiyaku (Japan).


Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Tenosynovitis Drugs Market?
The Tenosynovitis Drugs market is expected to see a CAGR of % during projected year 2021 to 2027.

2. Who are the top performing companies in Tenosynovitis Drugs Market?
Top performing companies in the Global Tenosynovitis Drugs market are GSK (United Kingdom), Pfizer (United States), Grunenthal (Germany), Sanofi (France), Bayer (Germany), AstraZeneca (United Kingdom), Lilly (United States), Endo International (Ireland), Merck (United States) and Yunnan Baiyao (China), to name a few.

3. What trending factors would impact Tenosynovitis Drugs Market growth most?
"Growing Use of Tenosynovitis Drugs for Arthritis Treatment" is seen as one of major influencing trends for Tenosynovitis Drugs Market during projected period 2021-2027.

Report Objectives / Segmentation Covered
By Product type
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Antibiotics
  • Corticosteroids

By End user
  • Hospitals
  • Drugstores
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Inflammatory Diseases
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Associated With the Intake of Drugs
    • 3.4. Market Trends
      • 3.4.1. Growing Use of Tenosynovitis Drugs for Arthritis Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tenosynovitis Drugs, by Product type, End user and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Tenosynovitis Drugs (Value)
      • 5.2.1. Global Tenosynovitis Drugs by: Product type (Value)
        • 5.2.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 5.2.1.2. Antibiotics
        • 5.2.1.3. Corticosteroids
      • 5.2.2. Global Tenosynovitis Drugs by: End user (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Drugstores
        • 5.2.2.3. Others
      • 5.2.3. Global Tenosynovitis Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Tenosynovitis Drugs (Price)
  • 6. Tenosynovitis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GSK (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Grunenthal (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lilly (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Endo International (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Yunnan Baiyao (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tenosynovitis Drugs Sale, by Product type, End user and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Tenosynovitis Drugs (Value)
      • 7.2.1. Global Tenosynovitis Drugs by: Product type (Value)
        • 7.2.1.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 7.2.1.2. Antibiotics
        • 7.2.1.3. Corticosteroids
      • 7.2.2. Global Tenosynovitis Drugs by: End user (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Drugstores
        • 7.2.2.3. Others
      • 7.2.3. Global Tenosynovitis Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Tenosynovitis Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tenosynovitis Drugs: by Product type(USD Million)
  • Table 2. Tenosynovitis Drugs Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2016-2021)
  • Table 3. Tenosynovitis Drugs Antibiotics , by Region USD Million (2016-2021)
  • Table 4. Tenosynovitis Drugs Corticosteroids , by Region USD Million (2016-2021)
  • Table 5. Tenosynovitis Drugs: by End user(USD Million)
  • Table 6. Tenosynovitis Drugs Hospitals , by Region USD Million (2016-2021)
  • Table 7. Tenosynovitis Drugs Drugstores , by Region USD Million (2016-2021)
  • Table 8. Tenosynovitis Drugs Others , by Region USD Million (2016-2021)
  • Table 9. South America Tenosynovitis Drugs, by Country USD Million (2016-2021)
  • Table 10. South America Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 11. South America Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 12. Brazil Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 13. Brazil Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 14. Argentina Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 15. Argentina Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 16. Rest of South America Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 17. Rest of South America Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 18. Asia Pacific Tenosynovitis Drugs, by Country USD Million (2016-2021)
  • Table 19. Asia Pacific Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 20. Asia Pacific Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 21. China Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 22. China Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 23. Japan Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 24. Japan Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 25. India Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 26. India Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 27. South Korea Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 28. South Korea Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 29. Australia Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 30. Australia Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 31. Rest of Asia-Pacific Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 32. Rest of Asia-Pacific Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 33. Europe Tenosynovitis Drugs, by Country USD Million (2016-2021)
  • Table 34. Europe Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 35. Europe Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 36. Germany Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 37. Germany Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 38. France Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 39. France Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 40. Italy Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 41. Italy Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 42. United Kingdom Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 43. United Kingdom Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 44. Netherlands Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 45. Netherlands Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 46. Rest of Europe Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 47. Rest of Europe Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 48. MEA Tenosynovitis Drugs, by Country USD Million (2016-2021)
  • Table 49. MEA Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 50. MEA Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 51. Middle East Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 52. Middle East Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 53. Africa Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 54. Africa Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 55. North America Tenosynovitis Drugs, by Country USD Million (2016-2021)
  • Table 56. North America Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 57. North America Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 58. United States Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 59. United States Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 60. Canada Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 61. Canada Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 62. Mexico Tenosynovitis Drugs, by Product type USD Million (2016-2021)
  • Table 63. Mexico Tenosynovitis Drugs, by End user USD Million (2016-2021)
  • Table 64. Company Basic Information, Sales Area and Its Competitors
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Tenosynovitis Drugs: by Product type(USD Million)
  • Table 75. Tenosynovitis Drugs Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2022-2027)
  • Table 76. Tenosynovitis Drugs Antibiotics , by Region USD Million (2022-2027)
  • Table 77. Tenosynovitis Drugs Corticosteroids , by Region USD Million (2022-2027)
  • Table 78. Tenosynovitis Drugs: by End user(USD Million)
  • Table 79. Tenosynovitis Drugs Hospitals , by Region USD Million (2022-2027)
  • Table 80. Tenosynovitis Drugs Drugstores , by Region USD Million (2022-2027)
  • Table 81. Tenosynovitis Drugs Others , by Region USD Million (2022-2027)
  • Table 82. South America Tenosynovitis Drugs, by Country USD Million (2022-2027)
  • Table 83. South America Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 84. South America Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 85. Brazil Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 86. Brazil Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 87. Argentina Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 88. Argentina Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 89. Rest of South America Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 90. Rest of South America Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 91. Asia Pacific Tenosynovitis Drugs, by Country USD Million (2022-2027)
  • Table 92. Asia Pacific Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 93. Asia Pacific Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 94. China Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 95. China Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 96. Japan Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 97. Japan Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 98. India Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 99. India Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 100. South Korea Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 101. South Korea Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 102. Australia Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 103. Australia Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 104. Rest of Asia-Pacific Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 105. Rest of Asia-Pacific Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 106. Europe Tenosynovitis Drugs, by Country USD Million (2022-2027)
  • Table 107. Europe Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 108. Europe Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 109. Germany Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 110. Germany Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 111. France Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 112. France Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 113. Italy Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 114. Italy Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 115. United Kingdom Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 116. United Kingdom Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 117. Netherlands Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 118. Netherlands Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 119. Rest of Europe Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 120. Rest of Europe Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 121. MEA Tenosynovitis Drugs, by Country USD Million (2022-2027)
  • Table 122. MEA Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 123. MEA Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 124. Middle East Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 125. Middle East Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 126. Africa Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 127. Africa Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 128. North America Tenosynovitis Drugs, by Country USD Million (2022-2027)
  • Table 129. North America Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 130. North America Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 131. United States Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 132. United States Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 133. Canada Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 134. Canada Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 135. Mexico Tenosynovitis Drugs, by Product type USD Million (2022-2027)
  • Table 136. Mexico Tenosynovitis Drugs, by End user USD Million (2022-2027)
  • Table 137. Research Programs/Design for This Report
  • Table 138. Key Data Information from Secondary Sources
  • Table 139. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tenosynovitis Drugs: by Product type USD Million (2016-2021)
  • Figure 5. Global Tenosynovitis Drugs: by End user USD Million (2016-2021)
  • Figure 6. South America Tenosynovitis Drugs Share (%), by Country
  • Figure 7. Asia Pacific Tenosynovitis Drugs Share (%), by Country
  • Figure 8. Europe Tenosynovitis Drugs Share (%), by Country
  • Figure 9. MEA Tenosynovitis Drugs Share (%), by Country
  • Figure 10. North America Tenosynovitis Drugs Share (%), by Country
  • Figure 11. Global Tenosynovitis Drugs share by Players 2021 (%)
  • Figure 12. Global Tenosynovitis Drugs share by Players (Top 3) 2021(%)
  • Figure 13. Global Tenosynovitis Drugs share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. GSK (United Kingdom) Revenue: by Geography 2021
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2021
  • Figure 19. Grunenthal (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Grunenthal (Germany) Revenue: by Geography 2021
  • Figure 21. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi (France) Revenue: by Geography 2021
  • Figure 23. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Bayer (Germany) Revenue: by Geography 2021
  • Figure 25. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 27. Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 28. Lilly (United States) Revenue: by Geography 2021
  • Figure 29. Endo International (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Endo International (Ireland) Revenue: by Geography 2021
  • Figure 31. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck (United States) Revenue: by Geography 2021
  • Figure 33. Yunnan Baiyao (China) Revenue, Net Income and Gross profit
  • Figure 34. Yunnan Baiyao (China) Revenue: by Geography 2021
  • Figure 35. Global Tenosynovitis Drugs: by Product type USD Million (2022-2027)
  • Figure 36. Global Tenosynovitis Drugs: by End user USD Million (2022-2027)
  • Figure 37. South America Tenosynovitis Drugs Share (%), by Country
  • Figure 38. Asia Pacific Tenosynovitis Drugs Share (%), by Country
  • Figure 39. Europe Tenosynovitis Drugs Share (%), by Country
  • Figure 40. MEA Tenosynovitis Drugs Share (%), by Country
  • Figure 41. North America Tenosynovitis Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GSK (United Kingdom)
  • Pfizer (United States)
  • Grunenthal (Germany)
  • Sanofi (France)
  • Bayer (Germany)
  • AstraZeneca (United Kingdom)
  • Lilly (United States)
  • Endo International (Ireland)
  • Merck (United States)
  • Yunnan Baiyao (China)
Additional players considered in the study are as follows:
Teikoku Seiyaku (Japan) , Teva (Israel) , Mikasa Seiyaku (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation